PROSIEBENSAT1 MED. (OTCMKTS:PBSFF)‘s stock had its “neutral” rating restated by equities researchers at Citigroup Inc in a note issued to investors on Tuesday, May 9th.

PBSFF has been the topic of several other reports. DZ Bank AG reaffirmed a “sell” rating on shares of PROSIEBENSAT1 MED. in a research report on Wednesday, April 19th. Barclays PLC raised PROSIEBENSAT1 MED. from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, January 25th.

PROSIEBENSAT1 MED. (OTCMKTS:PBSFF) traded up 2.0037% during mid-day trading on Tuesday, hitting $41.7807. 376 shares of the stock traded hands. The firm has a market capitalization of $9.56 billion and a P/E ratio of 21.4811. The company has a 50-day moving average of $43.17 and a 200 day moving average of $40.49. PROSIEBENSAT1 MED. has a 1-year low of $33.70 and a 1-year high of $51.22.

ILLEGAL ACTIVITY WARNING: “PROSIEBENSAT1 MED. (PBSFF) Rating Reiterated by Citigroup Inc” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/05/19/prosiebensat1-med-s-pbsff-neutral-rating-reiterated-at-citigroup-inc-updated.html.

Receive News & Stock Ratings for PROSIEBENSAT1 MED. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROSIEBENSAT1 MED. and related stocks with our FREE daily email newsletter.